Pavmed Inc. · NASDAQ:PAVM
Pavmed — IPO Roadshow (December 2015)
42 slides from Pavmed's IPO roadshow presentation, Dec 3, 2015
Slide 1: Lishan Aklog, MD, Chairman and CEO, December 3, 2015
1 TM L ISHAN A KLOG , MD Chairman and CEO DECEMBER 3, 2015
Slide 2: Disclaimer
2 Disclaimer PAVMED INC. (“PAVMED”) HAS FILED A REGISTRATION STATEMENT (INCLU DING A PROSPECTUS) WITH THE SEC FOR THE OFFERING TO WHICH THIS COMMUNICATION RELATES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGIST RATION STATEMENT AND OTHER DOCUMENTS PAVMED HAS FILED WITH THE SEC FOR
Slide 3: Company Overview
3 Company Overview
Slide 4: Innovative multi-product medical device company
4 I nnovative multi - product medical device company Unique, proven business model ▪ Speed to market ▪ Highly capital efficient ▪ High - margin, high - impact products in attractive markets Leadership team with strong track record of value creation ▪ Four successful single - product companies ▪ Rapi
Slide 5: Leadership team with strong record of value creation
5 LISHAN AKLOG, MD C HAIRMAN & CEO ▪ A.B. Physics, magna cum laude ▪ Phi Beta Kappa ▪ M.D., cum laude ▪ General Surgery Resident ▪ Cardiothoracic Surgery Resident ▪ Assistant Professor ▪ Associate Surgeon ▪ Associate Chief of Cardiac Surgery ▪ Assistant Professor ▪ Director of Minimally Invasive Car
Slide 6: Leadership team's prior track record of success
6 Leadership team’s prior track record of success A NGIO V AC ™ Endovascular device to remove large clots and other intravascular material V ENO P AX ™ Next - generation endoscopic vessel harvest device for coronary bypass surgery K ALEIDOSCOPE ™ Novel reversible IVC filter H OUDINI ™ Novel chronic
Slide 7: PAVmed builds on leadership team's prior success
7 PAVmed builds on leadership team’s prior success Created to leverage proven business model in a long - term multi - product company Access to seamless capital through the public capital markets Retain tight focus on capital and time efficiency Expanding pipeline Success not dependent on single pro
Slide 8: Lead products provide near-term value creation opportunities
8 Lead products provide near - term value creation opportunities NextCath Self - Anchoring Short - Term Catheters Target Commercialization Q4 - 2016 NextFlo Highly Accurate Disposable Infusion Pump T arget Commercialization Q4 - 2016 PortIO Long - term Implantable Vascular Access Device Target Comme
Slide 9: The PAVmed Business Model
9 The PAVmed Business Model
Slide 10: The PAVmed Business Model
10 The PAVmed Business Model Proven record advancing products from concept to commercialization with capital and time efficiency Stringent project selection criteria drive commercial opportunity Key business processes deliver capital and time efficiency Multi - product pipeline leverages capital eff
Slide 11: Proven record of delivering capital and time efficiency
11 Proven record of delivering capital and time efficiency 0 12 24 36 48 60 Typical Company PAVmed Model Months T IME TO 510( K ) C LEARANCE $0 $10,000,000 $20,000,000 $30,000,000 Typical Company PAVmed Model Dollars C APITAL T O 510( K ) C LEARANCE * Typical Company data from Markower, et al. FDA I
Slide 12: Project selection criteria drive commercial opportunity
12 Project selection criteria drive commercial opportunity COMMERCIAL OPPORTUNITY High - Margin High - Impact UNMET CLINICAL NEED/ ATTRACTIVE MARKET TECHNOLOGY PROFILE REGULATORY PATHWAY REIMBURSEMENT PROFILE
Slide 13: Key business processes deliver capital and time efficiency
13 Key business processes deliver capital and time efficiency CAPITAL AND TIME EFFICIENCY Maximize Value Creation LIGHT INFRASTRUCTURE/ LOW FIXED COSTS PARALLEL DEVELOPMENT PROCESSES OUTSOURCED BEST - IN - CLASS PROCESS EXPERTS
Slide 14: Multi-product pipeline enhances value creation
14 Multi - product pipeline enhances value creation ENHANCED VALUE CREATION ECONOMIES OF SCALE FLEXIBLE, DYNAMIC ALLOCATION OF RESOURCES FLEXIBLE COMMERCIALIZATION STRATEGY NON - BINARY SUCCESS
Slide 15: Flexible commercialization strategy accelerates value creation
15 Accelerate Revenue Growth Flexible commercialization s trategy accelerates value creation DIRECT SALES FORCE Call - point specific INDEPENDENT DISTRIBUTOR NETWORK Call - point specific REGULATORY CLEARANCE CORPORATE PARTNER Sales and Distribution A greement CORPORATE PARTNER Licensing agreement A
Slide 16: Product Pipeline
16 Product Pipeline
Slide 17: Lead products provide near-term value creation opportunities
17 PRODUCT ADDRESSABLE MARKET REGULATORY PATH COMMERCIALIZATION INITIAL CHANNEL TARGET DATE PortIO Long - term Implantable Vascular Access Devices $500M/$50M 510(k) Independent Distributors Q4 - 2016 Caldus Disposable Tissue Ablation Devices $200M/$100M 510(k) Independent Distributors Q2 - 2017 Disp
Slide 18: Patent applications by product
18 PRODUCT INVENTORS TITLE NUMBER DATE PortIO Aklog, deGuzman and Orphanos “Intraosseous Infusion Ports and Methods of Use” Application# US62/0.79.266 US14940889 PCT/US15/60669 Filed 13 - Nov - 2014 13 - Nov - 2015 13 - Nov - 2015 Caldus Aklog and deGuzman “Continuous Flow Balloon Catheter Systems a
Slide 19: PortIO
19 PortIO
Slide 20: PortIO Market Opportunity
20 Market Opportunity 1 iData Research Group, 2013 2 Baskin, et al . Lancet 2009 C LINICAL ▪ Long - term implantable vascular access devices A DDRESSABLE M ARKET ▪ All implantable ports 1 ~$500M ▪ Poor venous access patients ~$50M C URRENT D EVICE L IMITATIONS ▪ Intravascular component ▪ Occlusions
Slide 21: PortIO - The PAVmed Solution
21 PortIO - The PAVmed Solution P ORT IO ▪ Novel, implantable intraosseous vascular access device ▪ No intravascular component L ESS I NVASIVE ▪ Near percutaneous insertion/removal M ORE C OST E FFECTIVE ▪ Not prone to occlusions ▪ No need for regular flushes ▪ No radiographic confirmation necessary
Slide 22: Caldus
22 Caldus
Slide 23: Caldus Market Opportunity
23 Market Opportunity C LINICAL ▪ Ablation of pathologic soft tissues including tumors ▪ Renal denervation for refractory hypertension A DDRESSABLE M ARKET ▪ S oft tissue ablation ~$200M/$100M 1 Renal denervation ~$5B/$1B 2 C URRENT D EVICE L IMITATIONS ▪ Requires capital equipment (console) ▪ Expen
Slide 24: Caldus - The PAVmed Solution
24 Caldus - The PAVmed Solution C ALDUS ▪ Completely disposable tissue ablation devices ▪ Direct thermal ablation ▪ No console M ORE C OST E FFECTIVE ▪ No capital and maintenance costs ▪ Lower procedural cost while maintaining margin ▪ Higher temperatures allow shorter ablation times E XPANDED M ARK
Slide 25: CarpX
25 CarpX
Slide 26: CarpX Market Opportunity
26 Market Opportunity C LINICAL ▪ Carpal tunnel syndrome (CTS) ▪ Most common occupational injury A DDRESSABLE M ARKET ▪ ~2 million patients 1 ▪ 350,000 surgeries annually 1 ▪ All CTS patients $1.5B Current Surgical Patients $750M C URRENT D EVICE L IMITATIONS ▪ Invasive surgical procedure ▪ Endoscop
Slide 27: CarpX - The PAVmed Solution
27 CarpX - The PAVmed Solution C ARP X ▪ Completely percutaneous CTS device L ESS I NVASIVE ▪ Truly percutaneous ▪ No surgical incision or dissection M ORE C OST E FFECTIVE ▪ Shift procedures interventional lab or office ▪ Shorten procedural times F EWER C OMPLICATIONS ▪ Better nerve protection ▪ Gr
Slide 28: NextCath
NextCath SK PAvmed
Slide 29: NextCath Market Opportunity
29 Market Opportunity C LINICAL ▪ Short - term catheters including peripheral venous catheters (PVC ) A DDRESSABLE M ARKET 1 ▪ 90% of inpatients receive a PVC ▪ S hort - term vascular catheters ~$2B Peripheral venous catheters ~$1B C URRENT D EVICE L IMITATIONS ▪ Catheter dislodgement results in inc
Slide 30: NextCath - The PAVmed Solution
30 NextCath - The PAVmed Solution N EXT C ATH ▪ Self - anchoring, short - term catheters ▪ Integrated semi - stiff helical portion ▪ Applicable to most, if not all, short - term catheters M ORE C OST E FFECTIVE ▪ Eliminate costly catheter securement devices ▪ Less monitoring of catheter security ▪ F
Slide 31: NextFlo
31 NextFlo
Slide 32: NextFlo Market Opportunity
32 Market Opportunity C LINICAL ▪ Disposable infusion pumps (DIP) ▪ Increasing numbers receiving infusions outside hospital A DDRESSABLE M ARKET ▪ DIPs for home use ~$500M C URRENT D EVICE L IMITATIONS ▪ Highly inaccurate in actual use ▪ Dependent on operating conditions ▪ U nsuitable for use with m
Slide 33: NextFlo - The PAVmed Solution
33 NextFlo - The PAVmed Solution N EXT F LO ▪ Highly accurate disposable infusion pump ▪ Passive variable flow resistor design F EWER C OMPLICATIONS ▪ Prevent complications from infusions running too slow or fast M ORE C OST E FFECTIVE ▪ Reduce or eliminate need for trained healthcare personnel ▪ De
Slide 34: The PAVmed Team
34 The PAVmed Team
Slide 35: Experienced management team
35 Experienced management team LISHAN AKLOG, MD C HAIRMAN & CEO ▪ A.B. Physics, magna cum laude ▪ Phi Beta Kappa ▪ M.D., cum laude ▪ General Surgery Resident ▪ Cardiothoracic Surgery Resident ▪ Assistant Professor ▪ Associate Surgeon ▪ Associate Chief of Cardiac Surgery ▪ Assistant Professor ▪ Direc
Slide 36: Board of Directors with industry and capital markets experience
36 Board of Directors with industry and capital markets experience LISHAN AKLOG, MD Chairman, Chief Executive Officer MICHAEL GLENNON Vice - Chairman RONALD M. SPARKS Director Nominating Committee Chair ▪ Former Healthcare Industry Executive, Avista Capital Partners ▪ Former Chairman and CEO, Navily
Slide 37: Multi-Specialty Medical Advisory Board of renowned physician innovators
37 Multi - Specialty Medical Advisory Board of renowned physician innovators ALBERT CHIN MD ▪ Co - founding Partner and Chief Innovation Officer, Pavilion Medical Innovations ▪ Former Vice President of Research and Chief Innovation Officer, Maquet Cardiovascular/ Guidant Cardiac Surgery ▪ Inventor o
Slide 38: The Future of PAVmed
38 The Future of PAVmed
Slide 39: Internal innovation engine
39 Internal innovation engine ▪ Extracorporeal circulation (ECMO) cannulas ▪ Left atrial access for transcatheter mitral intervention ▪ Endotracheal intubation ▪ Sleep apnea ▪ Laparoscopic hernia r epair External partnerships ▪ Individual clinician i nnovators ▪ Academic m edical center tech transfe
Slide 40: Near- and long-term opportunities: Upcoming 2016 Milestones
40 Near - and long - term opportunities for value creation Complete lead product non - provisional patent applications PortIO FDA submission NextCath FDA submission NextFlo FDA submission PortIO FDA clearance and initial commercialization Caldus General FDA submission Caldus RND CE Mark submission C
Slide 41: Near- and long-term opportunities for value creation
41 Near - and long - term opportunities for value creation Rapidly advance lead products to commercialization Execute commercialization strategy Expand pipeline S HAREHOLDER V ALUE
Slide 42: PAVmed Investment Highlights
42 Unique, Proven Business Model Broad, Expanding Pipeline of Innovative Products World - Class Board and Advisors Leadership Team with Strong Record of Value Creation PAVmed Investment Highlights TM